Pharmacokinetics of sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is an approved oral treatment for hyperkalemia. It binds selectively to potassium in the gastrointestinal tract and eliminates it from the body through increased fecal excretion. This study describes the pharmacodynamic response to this drug in patients with hyperkalemia. The pharmacodynamic response was modeled from 7 phase 2 and 3 clinical trials, involving 2,369 patients and 25,764 potassium determinations. The modeled pharmacodynamic response adequately described changes in serum potassium concentration during the correction and maintenance phase of hyperkalemia.